Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers March 23, 2019
Pharmacy Choice - Pharmaceutical News - AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors [Palestine News Agency (WAFA)] - March 23, 2019

Pharmacy News Article

 1/8/19 - AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors [Palestine News Agency (WAFA)]

(GlobeNewswire) - AVROBIO, Inc. (NASDAQ: AVRO) (the Company), a clinical-stage gene therapy company, today announced the appointment of Philip J. Vickers, Ph.D., to its Board of Directors. Dr. Vickers brings a wealth of global pharmaceutical and biotechnology expertise to AVROBIO, with more than 25 years experience in the development and approval of innovative biologics and small molecules to treat diseases in a wide range of therapeutic areas. The Company also announced that Scott Requadt is transitioning off AVROBIOs board to become CEO of a Blackstone portfolio company.

Phil is a great addition to our Board, said Geoff MacKay, President and CEO of AVROBIO. His deep knowledge of lysosomal storage disorders, real and broad industry leadership and his experience leading Shires R&D with 75% of about 40 clinical development programs in rare diseases - are all invaluable in AVROBIOs next stage of growth. Id also like to acknowledge the significant contributions of Scott Requadt to AVROBIO and congratulate him on his new CEO role.

Dr. Vickers currently serves as President and CEO of Northern Biologics, Inc., a company focused on the development of monoclonal antibodies as immuno-oncology therapeutics to treat targeted populations of cancer patients. Prior to joining Northern Biologics, from 2010 to 2017, Phil was Global Head of Research and Development at Shire, where he was responsible for overseeing preclinical research and development, clinical research, regulatory affairs, and medical affairs. Phil oversaw Shires growing product portfolio and, as Executive Vice-President and a member of Shires Executive Committee, he played a key role in developing and executing Shires global business strategy, with a particular focus on rare diseases. Phil is also a member of the board of directors of Revance Therapeutics. Prior to joining Shire, Phil had roles of increasing responsibility in drug discovery in a range of therapeutic areas at Merck, Pfizer, Boehringer-Ingelheim and Resolvyx. Phil holds a Ph.D. in Biochemistry from the University of Toronto, and a Bachelor of Science degree in Applied Biochemistry from the University of Salford, Manchester U.K. He was also a Visiting Fellow at the National Cancer Institute in Bethesda, Maryland.

About AVROBIO, Inc. AVROBIO, Inc., is a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose. AVROBIOslentiviral-based gene therapiesemploy hematopoietic stem cells that are collected from the patient and then modified with a lentiviral vector to insert a functional copy of the gene that is defective in the target disease. AVROBIOis focused on the development of its gene therapy, AVRRD01, inFabry disease, as well as additional gene therapy programs in otherlysosomal storage disordersincluding Gaucher disease, cystinosisand Pompedisease.AVROBIOis headquartered inCambridge, MAand has offices inToronto, ON. For additional information,

Forward-Looking Statements

Various express or implied statements in this release concerning AVROBIOs future expectations, plans and prospects, including without limitation, its expectations regarding the growth of its business, and the development and the continued progress of AVROBIOs programs, including the therapeutic potential of its product candidates and the development thereof, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on managements current expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIOs product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any of AVROBIOs ongoing or planned clinical trials, the risk that AVROBIO may not realize the intended benefits of efforts to optimize its platform, and the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIOs product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIOs actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in AVROBIOs Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, as well as discussions of potential risks, uncertainties and other important factors in AVROBIOs subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Investor Contact:

Christopher F. Brinzey

Westwicke Partners


Media Contact:

Kathryn Morris

The Yates Network


(c) 2019 Palestine News & Information Agency (WAFA). All rights reserved. Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Mar 24: A Look Inside the Top 200 Drugs
Mar 25: Medication Use During Pregnancy & Lactation
Mar 26: Nutrigenomics - Nutritional Influences on the Genome
Mar 27: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Mar 28: Alternatives and Complements to Prescription Pain Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement